Skip to Content
Merck
All Photos(1)

Documents

Safety Information

T4019

Sigma-Aldrich

Trypsin−Agarose

buffered aqueous suspension, from bovine pancreas trypsin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

MDL number:
MFCD00082094
UNSPSC Code:
12352204
eCl@ss:
42020142
NACRES:
NA.54

biological source

bovine pancreas (trypsin)

form

buffered aqueous suspension

concentration

≥15 units/mL (packed gel)

extent of labeling

≥15 units per mL (packed gel)

matrix

beaded agarose

storage temp.

2-8°C

Related Categories

General description

The trypsin molecule has two domains: one is related to the enzyme active site and the tryptophan residues; the other is related to the 8-anilinonaphthalene-1-sulfonate binding.

Application

An experimental approach using SDS-PAGE, in-gel trypsin digestion and proteomic analysis identified five endosomal proteins. Trypsin cleavage of the high-risk HPV-16 E5 protein (16E5) generates a unique four-amino acid C-terminal peptide that serves as a marker for E5 expression in transfected cells and epithelial cell lines containing integrated and episomal HPV-16 DNA.

Unit Definition

One unit will hydrolyze 1.0 μmole of BAEE per min at pH 8.0 at 30 °C (titrimetric assay).

Physical form

Suspension in approx. 10 mM acetic acid, pH 3.2, containing preservative

Preparation Note

TPCK-treated

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H317

Hazard Classifications

Skin Sens. 1

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

ISHL Indicated Name

Substances Subject to be Indicated Names

ISHL Notified Names

Substances Subject to be Notified Names

JAN Code

T4019-BULK:
T4019-25UN:4548173212920
T4019-50UN:4548173212937
T4019-VAR:
T4019-100UN:4548173212913

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ziad Sahab et al.
Journal of virology, 86(17), 9465-9473 (2012-06-29)
The high-risk human papillomavirus type 16 (HPV-16) E5 protein (16E5) induces tumors in a transgenic mouse model and may contribute to early stages of cervical carcinogenesis. Although high-risk E5 expression is generally thought to be lost during the progression to
Fuying Chen et al.
EMBO molecular medicine, 14(5), e14904-e14904 (2022-04-02)
In this report, we discovered a new entity named cataract, alopecia, oral mucosal disorder, and psoriasis-like (CAOP) syndrome in two unrelated and ethnically diverse patients. Furthermore, patient 1 failed to respond to regular treatment. We found that CAOP syndrome was caused
Lucilene Delazari dos Santos et al.
Proteomics, 12(17), 2682-2693 (2012-07-05)
It is well known that the activation of mast cells due to the binding of mastoparan to the G(α) subunit of trimeric G proteins involves exocytosis regulation. However, experimental evidence in the literature indicates that mastoparan can also activate certain
Anna Kutschenko et al.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 130(6), 1066-1073 (2019-03-16)
Botulinum neurotoxin serotypes A and B (BoNT/A & B) are highly effective medicines to treat hyperactive cholinergic neurons. Due to neutralizing antibody formation, some patients may become non-responders. In these cases, the serotypes BoNT/C-G might become treatment alternatives. BoNT/D is
Kevin J Roberts et al.
Scientific reports, 11(1), 19422-19422 (2021-10-02)
Anti-TNFα and anti-IL-23 antibodies are highly effective therapies for Crohn's disease or ulcerative colitis in a proportion of patients. V56B2 is a novel bispecific domain antibody in which a llama-derived IL-23p19-specific domain antibody, humanised and engineered for intestinal protease resistance

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service